iPS Cells & Regenerative Medicine– category –
-
Century Therapeutics to Present iPSC-Derived CNTY-813 (Featuring Allo-Evasion™ 5.0) for Type 1 Diabetes at ADA 86th Scientific Sessions
Benzinga USA Overview Century Therapeutics is scheduled to deliver an oral presentation on its innovative iPSC-derived islet cell replacement therapy, CNTY-813, for Type 1 diabetes at the American Diabetes Association (ADA) 86th Scientif... -
REPROCELL Unveils AI-Designed CRISPR for Hypoimmune iPSC Engineering, Accelerating Off-the-Shelf Cell Therapy Development
REPROCELL Japan Overview REPROCELL announced that its StemEdit platform, integrating AI-designed CRISPR with optimized workflows, has achieved high gene-editing efficiency and reduced off-target activity in induced pluripotent stem cells... -
Japan Nears Approval of BioCardia’s CardiAMP Heart Failure Cell Therapy: PMDA Issues Consultation Record Supporting Regulatory Submission
Longevity.Technology Japan Overview Japan has moved closer to approving BioCardia's CardiAMP cell therapy for ischemic heart failure with reduced ejection fraction (HFrEF). Japan's Pharmaceuticals and Medical Devices Agency (PMDA) issued... -
CRISPR Gene Editing Utilized: First Leishmaniasis Vaccine Receives FDA IND Approval, Advancing to Phase 1 Clinical Trial
Ohio State News USA Overview The first leishmaniasis vaccine, developed by researchers at Ohio State University, is set to begin a Phase 1 clinical trial after receiving Investigational New Drug (IND) approval from the FDA. This innovati... -
Beam Therapeutics Stock Rises 2.04% After Receiving Triangle Business Journal’s 2026 Life Sciences Award, Signaling Heightened Market Optimism
Traders Union USA Overview Beam Therapeutics received the prestigious 2026 Life Sciences Award from Triangle Business Journal, acknowledging its innovative contributions. Concurrently, the company's stock experienced a 2.04% rise, reflec... -
High Volume of CRISPR Therapeutics Call Options Reflects Strong Market Confidence in Gene-Editing Pipeline
MarketBeat USA Overview On June 4, 2026, CRISPR Therapeutics (NASDAQ:CRSP) experienced exceptionally high call option trading volume, indicating robust investor interest in the company. This active trading reflects sustained confidence f... -
Intellia Therapeutics to Unveil Additional Phase 3 HAELO Data for Lonvo-z, a Hereditary Angioedema Therapy, at EAACI Annual Congress
Quiver Quantitative USA Overview Intellia Therapeutics announced it would present additional Phase 3 HAELO clinical trial data for lonvo-z (lonvoguran ziclumeran), its CRISPR-based gene-editing therapy for hereditary angioedema (HAE), at... -
Fate Therapeutics’ iPSC-Derived CAR T Therapy FT836 Shows Tumor Reduction and Favorable Safety Profile in KRASwt Colorectal Cancer Phase 1 Data at ASCO
GlobeNewswire (Fate Therapeutics Press Release) USA Overview Fate Therapeutics presented preliminary Phase 1 clinical data for its iPSC-derived, off-the-shelf CAR T-cell therapy, FT836, at the 2026 American Society of Clinical Oncology (... -
Vyjuvek Secures UK MHRA Approval; REGENXBIO’s RGX-202 Achieves Primary Endpoint in Duchenne Muscular Dystrophy Phase 3 Trial
YouTube (Lucid Quest) USA Overview A May 28, 2026, update reported that Vyjuvek, a gene therapy for dystrophic epidermolysis bullosa, has received UK MHRA approval. Concurrently, REGENXBIO's RGX-202, a gene therapy for Duchenne muscular ... -
EMA Initiates Review of Otarmeni’s Hereditary Hearing Loss Gene Therapy; Eli Lilly Announces Phase 2 Plans for VERVE-102 in Cardiovascular Disease
LucidQuest Ventures USA Overview Key developments in the cell and gene therapy sector were reported on May 28, 2026, with Otarmeni's hereditary hearing loss gene therapy entering EMA review. Eli Lilly detailed its Phase 2 clinical trial ...
